Product Description
Brinzolamide ophthalmic (eye) drops is used to treat increased pressure in the eye caused by open-angle glaucoma or a condition called ocular hypertension. Both eye conditions are caused by high pressure in your eye and can lead to pain from pressure in your eye and then can eventually harm your vision. This medicine can help you keep your sight by reducing the pressure in your eye and stopping eye pain. (Sourced from: https://www.mayoclinic.org/drugs-supplements/brinzolamide-ophthalmic-route/description/drg-20062342)
Mechanisms of Action: CA Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical,Ophthalmic
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Hypertension | Glaucoma | Glaucoma, Open-Angle
Known Adverse Events: Dysgeusia | Environmental Hypersensitivity | Keratoconjunctivitis Sicca
Company: Alcon
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Greece, India, Russia, United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Glaucoma|Glaucoma, Open-Angle|Hypertension
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BECRO/OV/BRINZOTIM | P3 |
Unknown Status |
Hypertension|Glaucoma |
2025-06-30 |
|
| 2022-002524-12 | P3 |
Active, not recruiting |
Glaucoma|Hypertension |
2024-01-29 |
|
| BRIN-20-01 | P3 |
Completed |
Glaucoma, Open-Angle|Hypertension |
2022-12-29 |
|
| PRG-NY-20-002 | P3 |
Completed |
Hypertension|Glaucoma, Open-Angle |
2022-03-11 |
95% |